Who is Mobius Therapeutics?
Mobius Therapeutics was founded in 2006 on the principle of enhancing the delivery of healthcare to the ophthalmic market. It’s flagship product, Mitosol, was FDA approved in 2012 and received Medicare reimbursement in 2013. Mitosol is the only FDA-approved formulation of ophthalmic MMC.
What do you mean by Legal Developments?
The implementation of the Drug Quality and Security Act (DQSA) is an ongoing process that is scheduled to end in 2024. As of Jan. 2017, approximately two-thirds of the Act have not taken full effect. Some of the most important regulations will begin enforcement this year and accelerate quickly. Staying informed will be an important component to remain in compliance of this far reaching law.